Selected Grants
An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
Clinical TrialPrincipal Investigator · Awarded by Henlius USA Inc. · 2025 - 2030A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations
Clinical TrialPrincipal Investigator · Awarded by Iambic Therapeutics, Inc. · 2025 - 2030Phanes Therapeutics / The SKYBRIDGE study, an Open-label, Multicenter, Dose Escalation and Dose Expansion Phase 1/2 Study with PT217 Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients with NeuRoendocrIne Carcinomas Th
Clinical TrialPrincipal Investigator · Awarded by Phanes Therapeutics, Inc. · 2025 - 2030An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Clinical TrialPrincipal Investigator · Awarded by ORIC Pharmaceuticals, Inc. · 2024 - 2029A randomized pilot study comparing the feasibility of using a virtual agent vs. an off-site human agent to onboard oncology patients to remote patient AI monitoring devices
Clinical TrialPrincipal Investigator · Awarded by NTT DATA Americas, Inc. · 2025 - 2029BGBC016 STK11 NSCLC
Clinical TrialPrincipal Investigator · Awarded by BerGenBio ASA · 2023 - 2028CNS PATTERN: CNS Progression After Targeted Therapy and Effect of Radiation in NSCLC
FellowshipPrincipal Investigator · Awarded by Lung Cancer Initiative of North Carolina · 2025 - 2026External Relationships
- Eli Lilly & Co. , AstraZeneca
- Genentech
- Navya
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.